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ABSTRACT 
 
Background and Objectives: The selection of alternative treatment options with antibiotic combinations may 
be used for successful managing of multidrug-resistant Acinetobacter baumannii. The aim of this study was to 
determine the synergistic effects of ampicillin-sulbactam combined with either levofloxacin or tigecycline against MDR A. 
baumannii.
Materials and Methods: A total 124 of  A.baumannii isolates collected from clinical samples of hospitalized patients which 
assessed for antibiotic susceptibility using disk diffusion method. E-test was used on 10 MDR A. baumannii isolates to de-
termine the minimum inhibitory concentration (MIC) of ampicillin-sulbactam, levofloxacin and tigecycline. Any synergistic 
effects were evaluated at their own MIC using E-test assay at 37°C for 24 hours. Synergy was defined as a fractional inhib-
itory concentration index (FICI) of ≤0.5.
Results: Levofloxacin plus ampicillin-sulbactam combination was found to have synergistic effects (FIC index: 
≤0.5) in 90% of the isolates, but there was no synergistic effect for ampicillin-sulbactam/tigecycline and tigecy-
cline/levofloxacin combination. The antagonist effect in 50% of isolates (FIC index: >2) showed in combination of 
levofloxacin/tigecycline. 
Conclusion: The emergence of multidrug A. baumannii isolates requires evaluating by combination therapy. The combina-
tion of levofloxacin plus a bactericidal antibiotic such as ampicillin-sulbactam is recommended. Results should be confirmed 
by clinical studies.
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INTRODUCTION
During the last decades, emergence of antibiotic 
resistance among A. baumannii has been considered 
as a worldwide alarm. Importance to search new an-
timicrobial agents and/or therapeutic strategies has 
been a major challenge in the field of infectious dis-
eases. Multidrug-resistant (MDR) A. baumannii is 
one of the main causes of severe hospital-acquired 
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infections (1). Although, there are various effective 
antibacterial drugs, but currently polymyxin B and 
colistin, regardless of their adverse side effects, are 
only remaining options for treatment and control of 
infections caused by this pathogen (2, 3). The combi-
nation use of antibiotics has been shown to decreas-
es the necessary therapeutic doses of antibacterial 
agents, which lower their risk of adverse reactions 
and drug toxicity (4).
Sulbactam is a beta-lactamase inhibitor that inhib-
its the activity of some plasmid-mediated beta-lact-
amases (5). Combination of sulbactam with ampicil-
lin results to widened spectrum of activity against 
organisms with plasmid-mediated beta-lactamases. 
Tigecycline inhibits bacterial protein synthesis by 
acting on the 30S ribosomal subunit and prevents 
amino acids to incorporate in process of elongating 
peptide chains (6). Tigecycline is a bacteriostatic and 
it has extended post antibiotic effect, which shows 
broad spectrum activity against Gram-negative or-
ganisms. The decreased susceptibility of Gram-neg-
ative organisms to tigecycline mostly mediated by 
theirs multidrug efflux pumps (7). Levofloxacin is a 
broad-spectrum bactericidal antibiotic that is active 
against Gram-negative bacteria. Its function mediat-
ed by inhibiting the DNA gyrase and topoisomerase 
IV. Unfortunately, the therapeutic choices for exten-
sively drug-resistant (XDR) Acinetobacter are usu-
ally limited to polymyxins and tigecycline. Empiric 
antibiotic therapy for A. baumannii should be cho-
sen based on local susceptibility patterns. It should 
be containing a broad-spectrum cephalosporin, a 
combination including sulbactam, or a carbapenem. 
A fluoroquinolone, an aminoglycoside, or colistin is 
second agent alternatives. The selection of alterna-
tive treatment options with antibiotic combinations 
may be used for successful managing of MDR A. 
baumannii infections. The aim of the present study 
was to perform in vitro research, using the eplisome-
ter method; to investigate the efficacy of tigecycline 
combined with either levofloxacin or ampicillin-sul-
bactam of MDR A. baumannii isolates.
 
MATERIALS AND METHODS
 
  Bacterial strains and antibiotic susceptibility. The 
antibiotic susceptibility test of 124 isolates was done 
using Kirby-Bauer disk diffusion on Mueller-Hin-
ton agar plates, and the results were interpreted ac-
cording to the Clinical and Laboratory Standards 
Institute (CLSI) criteria (8). The antibacterial disks 
were purchased from MAST, Merseyside, UK were 
as follow: piperacillin (100µg), ampicillin-sulbact-
am (10/10µg), piperacillin-tazobactam (100/10µg), 
cefotaxime (30µg), ceftazidime (30µg), ceftriaxone 
(30µg), imipenem (10µg), meropenem (10µg), genta-
micin (10µg), amikacin (30µg), tetracycline (30µg), 
ciprofloxacin (5µg), levofloxacin (5µg), trimetho-
prim-sulfamethoxazole (1.25/23.75mg); polymyxin B 
(300 IU) and colistin (10µg). Escherichia coli ATCC 
25922 were used as quality control in each suscepti-
bility test. Multi-drug resistance (MDR) is defined 
as resistance to three or more classes of antibiotics.
All isolates were subjected to PCR to determine the 
presence of blaoxa-51 gene, which is specific to A. bau-
mannii. They were verified by blast analysis in the 
database (http://www.ncbi.nlm.nih.gov/GenBank). 
Primer pairs used for blaOXA-51 gene with 353 base pair 
chain shown as follows: Forward: 5'- TAATGCTTT-
GATCGGCCTTG-3', and Reverse: 5'-TGGATTG-
CACTTCATCTTGG-3'. blaOXA-51 PCR product was 
sequenced by Macrogen Company (Seoul, Korea), 
and the alignments were prepared with the Chromas 
1.7.5 software and BLAST in NCBI. A. baumannii 
ATCC 19606 was used as reference strain. Minimum 
inhibitory concentrations (MICs) of levofloxacin, 
ampicillin-sulbactam, and tigecycline were obtained 
by E-test according to CLSI recommendations. In-
terpretation criteria for susceptibility tests were 
based on CLSI guidelines (8).
Synergy testing. For this study, 10 multidrug-re-
sistant clinical isolates of A. baumannii were select-
ed. Preparing fresh passages of the bacterial suspen-
sions performed the synergy tests. The amount of 
100µl bacterial suspensions prepared with 0.5 Mac-
Farl and of standard turbidity, and was spread onto 
150mm Muller–Hinton agar plates. E-test® strips 
(Liofilchem, Roseto Degli Abruzzi, Italy), for ampi-
cillin/sulbactam and tigecycline were placed sepa-
rately onto the plates. The exact site at which the strip 
was placed was marked on the plate. Then the plates 
were incubated for just 1h at 37°C. Following incu-
bation, the E-test® strips were aseptically removed 
from the plates and the E-test® strip for levoflox-
acin was placed onto the marked space, accurately 
overlapping the first strip. Plates were then incubated 
for 24h at 37°C and the MIC values were recorded. 
The MIC was interpreted as the value at which the 
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inhibition zone intersected the scale on the E strip. 
The obtained MIC results were converted to qualita-
tive categories (susceptible, intermediate, and resis-
tant) using CLSI guidelines (8), and compared with 
Pseudomonas aeruginosa ATCC 27853, as reference 
strain, was used as a quality control strain. Levoflox-
acin MIC (≤ 2 µg/ml sensitive, 4µg/ml intermediate, 
≥8µg/ml resistant); ampicillin/sulbactam (≤ 8/4µg/
ml sensitive, 16/8µg/ml intermediate, ≥32/16µg/ml 
resistant); tigecycline (≤ 2µg/ml sensitive, 4µg/ml 
intermediate, ≥8 µg/ml resistant). 
Fractional inhibitory concentration (FIC). To 
evaluate the effect of the combination, the fraction-
al inhibitory concentration (FIC) was calculated for 
each antibiotic in each combination as follows:
FIC index=FIC of drug A+FIC of drug B; where 
FIC of drugA=MIC of drug A in combination/MIC 
of drug A alone; and FIC of drug B=MIC of drug 
B in combination/MIC of drug B alone. An FIC in-
dex of ≤0.5 was defined as synergism, FIC index of 
0.51–0.99 defined as additive effect, FIC index of 1–2 
defined as indifference. The FIC index of >2 defined 
as antagonism (9).
 
RESULTS
The phenotypic resistance patterns represented 
that the isolates are resistant to cefepime, cefotax-
ime, ceftazidime, ceftriaxone, ciprofloxacin, levo-
floxacin, piperacillin, and susceptible to colistin 
and polymyxin B (Table 1). In vitro antibacterial 
activity of tested antibiotics combinations against 
MDR A. baumannii isolates shown in Table 2, Table 
3, and Table 4. Synergism was seen using levoflox-
acin plus ampicilin/sulbactam combination in 90% 
of tested isolates (Table 5). Antagonistic effect was 
seen in 50% of isolates with tigecycline plus levo-
floxacin combination. In this study, the combination 
of tigecycline plus ampicilin/sulbactam and tigecy-
cline plus levofloxacin combination did not observe 
in vitro synergy. Indifferent effect was observed in 
70% with combination of ampicilin/sulbactam plus 
tigecycline. The combination of tigecycline with 
levofloxacin demonstrated 20% additive and 30% in-
different effect against MDR A. baumannii isolates.
DISCUSSION
   The emergence of antibiotic resistance A. bauman-
nii is increasing at an alarming rate all around the 
world and especially in Iran (10-16). Data from the 
surveillance of antimicrobial resistance studies in Iran 
showed high resistance rate to ceftazidime, imipen-
em, or meropenem (11, 13-14). MDR A. baumannii 
is a noticeable challenge in Iranian hospitals (13-16). 
Table 1. Summary of resistance: phenotypic characteristics of the ten multidrug resistance A. baumannii isolates selected for 
synergy test
Strain No.
1
2
3
4
5
6
7
8
9
10
PRL
R
R
R
R
R
R
R
R
R
R
SAM
R
R
R
R
R
S
S
R
S
R
PTZ
R
R
R
R
R
R
R
R
S
R
CAZ
R
R
R
R
R
R
R
R
R
R
CPM
R
R
R
R
R
R
R
R
R
R
CTX
R
R
R
R
R
R
R
R
R
R
CRO
R
R
R
R
R
R
R
R
R
R
MEM
R
R
R
R
R
S
R
R
S
R
IMI
R
R
R
R
R
S
S
R
S
R
AK
S
R
R
S
R
S
S
R
S
I
GM
R
R
R
R
R
I
R
R
I
R
LEV
R
R
R
R
R
R
R
R
R
R
CIP
R
R
R
R
R
R
R
R
R
R
T
R
R
R
R
R
S
R
R
R
I
TS
R
R
R
R
R
I
R
R
R
R
CO
S
S
S
S
S
S
S
S
S
S
PB
S
S
S
S
S
S
S
S
S
S
R: Resistance S: Sensitive I: Intermediate
PRL: Piperacillin; SAM: Ampicillin-sulbactam; PTZ: Piperacillin-tazobactam; CAZ: Ceftazidime; CPM:Cefepime; CTX: 
Cefotaxime; CRO: Ceftriaxone; MEM: Meropenem; IMI: Imipenem; AK:Amikacine; GM:Gentamicin; LEV:Levofloxacin; 
CIP:Ciprofloxacin; T:Tetracycline,TS:Trimethoprim-sulfamethoxazole; CO: Colistin; PB: Polymyxin B
COMBINATION OF ANTIBIICS AGAINST MDR ACINETOBACTER
IRAN. J. MICROBIOL.  Volume 9 Number 1 (February 2017) 19-25                21 http://ijm.tums.ac.ir
http://ijm.tums.ac.ir
Table 2. In vitro antibacterial activity of ampicilin/sulbactam with levofloxacin combinations against MDR A.baumannii 
isolates
Bacterial 
strain number
1
2
3
4
5
6
7
8
9
10
MIC (alone)
Levofloxacin
MIC µg/ml
32
32
32
16
32
32
32
32
32
32
MIC (alone)
ampicilin/sulbactam
MIC µg/ml
32
16
32
32
32
6
24
2
6
32
MIC combined
ampicilin/sulbactam plus Levofloxacin 
MIC µg/ml
4
4
4
3
6
0.75
4
4
0.75
6
FIC  
index
0.25
0.375
0.25
0.28
0.375
0.148
0.291
2.125
0.148
0.375
Interaction
Synergism
Synergism
Synergism
Synergism
Synergism
Synergism
Synergism
Antagonist
Synergism
Synergism
Table 3. In vitro antibacterial activity of levofloxacin with tigecycline combinations against MDR A. baumannii 
isolates
Bacterial
strain number
1
2
3
4
5
6
7
8
9
10
MIC (alone)
Levofloxacin
MIC µg/ml
32
32
32
16
32
32
32
32
32
32
MIC (alone)
Tigecycline
MIC µg/ml
4
12
16
0.75
16
1.5
4
2
16
4
MIC combined
Levofloxacin plustigecycline
MIC µg/ml
12
12
8
0.75
12
4
8
12
8
12
FIC 
index
3.375
1.375
0.75
1.05
1.125
2.79
2.25
6.375
0.75
3.375
Interaction
Antagonism
Indifference
Additive
Indifference
Indifference
Antagonism
Antagonism
Antagonism
Additive
Antagonism
Table 4. In vitro antibacterial activity of ampicilin/sulbactam with tigecycline combinations against ten MDR A. baumannii 
isolates
Bacterial 
strain number
1
2
3
4
5
6
7
8
9
10
MIC (alone)
ampicilin/sulbactam
MIC µg/ml
32
24
24
24
32
8
24
4
32
32
MIC (alone)
tigecycline
MIC µg/ml
8
16
16
1
16
4
12
2
16
8
MIC combined
ampicilin/sulbactam plustigecycline
MIC µg/ml
12
12
24
0.75
16
3
12
1
12
12
FIC 
index
1.875
1.25
2.5
0.78
1.5
1.125
1.5
0.75
1.125
1.875
Interaction
Indifference
Indifference
Antagonism
Additive
Indifference
Indifference
Indifference
Additive
Indifference
Indifference
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A. baumannii has the ability to develop resistance 
through some various means, leading to emergence of 
global drug-resistant isolates, which are more compli-
cated to treat and are related with a higher mortality 
rates than susceptible isolates. Prior carbapenems and 
fluoroquinolones exposure isolates are more related 
with colonization and unresponsiveness infections 
due to drug-resistant A. baumannii isolates.
   In our setting with high rate of resistance rate to 
the broad-spectrum cephalosporin, a combination of 
beta-lactam/beta-lactamase inhibitor and carbapenem, 
therapeutic options is polymyxins and possibly tige-
cycline. Colistin is currently the treatment of choice 
for infections caused by MDR A. baumannii. How-
ever, colistin administration alone is also related with 
significant nephrotoxicity and hetero- resistance in 
MDR A. baumannii clinical isolates. 
   Peerayeh et al. had studied in vitro activity of tige-
cycline and colistin against clinical isolates of A. 
baumannii isolated in several hospitals in Tehran and 
Bandar-Abbas, Iran (3). According to their results all 
isolates were sensitive to colistin and polymyxin-B. 
Moreover, based on the FDA criteria, the resistance 
rates for tigecycline were 20.8% and 17.6% in Teh-
ran and Bandar-Abbas, respectively (3). Tigecycline 
resistance is chiefly resulted from resistance-nodula-
tion-cell division (RND)-type transporters, mostly the 
AdeABC, AdeFGH and AdeIJK efflux pumps, but 
other resistance mechanisms have also been concerned 
(17). When two antimicrobial agents act concurrently 
on a pathogen, their effects may be synergism, antago-
nism indifference, or addition. All of these effects may 
be observed both in-vitro and in-vivo. Those effects 
that can be attained with combinations of antimicrobi-
al drugs may vary with different combinations and are 
specific for each kind of strain of microorganisms. For 
the antagonist effect, should be remembered that the 
combined action is less effective than that used alone.
   According to our results ampicilin/sulbactam and 
levofloxacin showed highly synergism effect in MDR 
A. baumannii strains isolated from patients (defined as 
a fractional inhibitory concentration index of < 0.5). 
In this study, levofloxacin failed in vitro activity as a 
single agent against the 10 clinical isolates. Levoflox-
acin and Ampicilin/sulbactam resistance were the fre-
quently identified isolates. However, levofloxacin and 
ampicilin/sulbactam combination showed a synergis-
tic effect against MDR A. baumannii isolates and in-
creased the antibiotic activity of each drug, suggesting 
that the combination may improve effects of both an-
tibiotics and combat drug-resistant bacteria that cause 
MDR A. baumannii infections. The MIC values of the 
combination were reduced in relation to the MIC val-
ues of each levofloxacin alone (Table 2). These results 
produce promises that levofloxacin can be used as 
combination therapy for infections by MDR A. bau-
mannii. Ampicilin/sulbactam and levofloxacin may 
apply different pharmacokinetic and pharmacody-
namic properties under in-vitro and in-vivo conditions. 
Further work on the pharmacokinetic parameters of 
this combination in vivo will be needed. In this study 
antagonist effects observed in half of isolates when 
used combination of levofloxacin plus tigecycline 
which is defined as a fractional inhibitory concentra-
tion index of > 2. Antagonism effect occurred when a 
bacteriostatic drug was given with a bactericidal one 
(18). While tigecycline, a bacteriostatic agent is used 
in combination with levofloxacin, a bactericidal drug, 
and their effects should be antagonized. Principe et al. 
shown that all 24 A. baumannii isolates were resistant 
to levofloxacin and piperacillin-tazobactam. Chequer 
board analysis performed with all antimicrobials in 
combination with tigecycline showed 5.9% synergy, 
85.7% indifference, and 8.3% antagonism. Tigecy-
cline showed synergistic activity with levofloxacin, 
amikacin, imipenem and colistin. Particularly, syner-
gistic effects were seen only among tigecycline resis-
tant isolate. Antagonistic interactions were observed 
for only one isolates to tigecycline/ampicillin-sulbac-
tam (19). The results of study of Petersen et al. on the 
Table 5. Synergy test results for ampicillin-sulbactam/tigecycline, levofloxacin/ ampicillin -sulbactam and tigecycline/levo-
floxacin combination against ten MDR A. baumannii isolates
Additive 
No. (%)
2(20)
0(0)
2(20)
Antagonostic
No. (%)
1(10)
0(0)
5(50)
Indifferent 
No. (%)
7(70)
1(10)
3(30)
Synergistic 
No. (%)
0(0)
9(90)
0(0)
Effect
Combination
Ampicillin-sulbactam/tigecycline
Levofloxacin/ampicillin-sulbactam
Tigecycline/levofloxacin
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interaction of tigecycline with 13 select antimicrobial 
agents against a wide variety of Gram-negative and 
Gram-positive isolates described that tigecycline in 
combination with ampicillin/sulbactam and levoflox-
acin resulted in no interaction or synergy. Antagonism 
was not seen for any combination (20). In vitro activ-
ities of levofloxacin in combination with tigecycline 
using a microbroth checkerboard technique showed 
that synergistic interaction for tigecycline-levofloxa-
cin combinations (21).
   The antagonism effect mainly occur if the bacte-
riostatic drug reaches the site of infection prior to 
bactericidal drug, or the killing of bacteria is essential 
for cure, and if only minimal effective doses of either 
drug in the pair are present. In addition, an unpredict-
ed variety of cellular responses to antagonistic drug 
combinations are possible. It signifies that multiple 
mechanisms that cause the interactions. Control of 
multidrug-resistant A. baumannii is concerned as an 
important worldwide problem. More recently, emer-
gence of extensively drug-resistant A. baumannii 
infections presents a significant challenge to global 
control. Prevention of drug-resistant Acinetobacter 
depends on early detection, control of spread, and pre-
venting establishment of endemic strains by avoiding 
exposure of microorganisms to a particularly valuable 
drug by limiting its use, especially at hospitals. Selec-
tion of the suitable treatment for MDR strains of A. 
baumannii is critical in practice, because usual labo-
ratory testing is unable to disclose the susceptibility of 
two agents from different classes of antibiotics. Most 
of the infectious diseases practitioners prefer to pre-
scribe two agents from distinct classes of antibiotics 
to prevent emergence of drug resistance and treatment 
failure. Sometimes, the synergy testing revealing the 
potential effectiveness of the two antibiotics in com-
bination, but it must be confirmed by the patient’s re-
sponse during clinical trials. In the other hand, in spite 
of sensitivity of the infectious agents against MDR A. 
baumannii, to 2 tested antibiotics in synergy testing, 
their use in patients may not thoroughly cure the infec-
tion, and it seems need to do more investigations. In 
combination therapy for MDR A. baumannii, the in-
fectious diseases clinician should avoid recommend-
ing two antibiotics, one from bactericidal class and the 
other from bacteriostatics. A limitation of this study is 
the use of inadequate isolates.
CONCLUSION
    In the present study, all of the isolated MDR A. bau-
mannii were resistant to all tested antibiotics except to 
colistin and polymixin B. It is an important alarming 
sign that represents a major epidemiological health 
concern and limits the therapeutic choices in criti-
cally ill patients with MDR A. baumannii infections. 
Ampicilin/sulbactam combined with levofloxacin 
revealed synergistic effect in the most MDR A. bau-
mannii isolates. The synergistic effect did not observe 
in levofloxacin/tigecycline, and ampicilin-sulbactam/
tigecycline combination. According to the results of 
this study the combination of levofloxacin plus a bac-
tericidal antibiotic such as ampicillin-sulbactam are 
recommended.
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